10 hours ago · FDA expands Novartis' Kisqali label to include early breast cancer patients.
Missing: preço | Show results with:preço
8 hours ago · $113.77, -0.09, -0.08% ...
Missing: preço | Show results with:preço
15 hours ago · Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk ... Price, Change, Volume. 24-10-08, 97.58 CHF, -0.15%, 2.69M. 24-10-07, 97.73 CHF ...
Missing: preço | Show results with:preço
48 minutes ago · Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and ...
12 hours ago · ... KISQALI - ribociclib succinate tab pack 200 mg daily dose, 400 mg daily dose (200 mg tab), 600 mg daily dose (200 mg tab). 2 • • •. •. KOSELUGO - selumetinib ...
Missing: preço | Show results with:preço
4 hours ago · Novartis' Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds. Sep 16, 2024. ESMO24: A cancer cachexia drug, VEGF enthusiasm and immunotherapy's ...
Missing: preço | Show results with:preço
6 hours ago · Comparatively steadier U.S. treasury yields also boosted investors' optimism, which was reflected in the form of positive price change on the bourses. ... Kisqali ...
Missing: preço | Show results with:preço
10 hours ago · ... Kisqali® (ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET) alone; consistent benefit and a well-tolerated safety ...
Missing: preço | Show results with:preço
7 hours ago · On Sept. 17, 2024, Novartis announced that the US Food and Drug Administration (FDA) has approved Kisqali in combination with an aromatase inhibitor (AI) ...
Missing: preço | Show results with:preço
16 hours ago · Bank of America cut shares of Novartis from a "buy" rating to a "neutral" rating and lowered their target price for the company from $135.00 to $130.00 in a ...
Missing: preço | Show results with:preço
